Generic Bactroban® Launches

Released: 01/28/2013   By: Mike Partridge, RPh

On January 25, 2013, Glenmark received final FDA approval for and commenced shipping the generic equivalent for GlaxoSmithKline’s branded product, Bactroban® (mupirocin) cream. Bactroban® had estimated total U.S. annual sales of approximately $70 million.
Bactroban is indicated for the treatment of secondarily infected traumatic skin lesions due to susceptible strains of S. aureus and S. pyogenes.